Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis


San Mateo, California, August 16, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that clinicians recently dosed the first patient with nonalcoholic steatohepatitis (NASH) in its FASCINATE-2 Phase 2b clinical trial.

Eduardo Bruno Martins, MD, DPhil, Sagimet’s chief medical officer, said, “The initiation of the Phase 2 clinical trial marks an important milestone for the evaluation of our lead candidate TVB-2640. Building from the data seen in our FASCINATE-1 Phase 2a clinical trial, we believe TVB-2640 has the potential to make a meaningful difference for patients with NASH, the most aggressive form of nonalcoholic fatty liver disease (NAFLD), for which there are no FDA-approved therapies.”

“After the robust and encouraging results from the Phase 2a study of TVB-2640, we are very excited to be enrolling individuals with NASH in the Phase 2b trial,” stated said Rohit Loomba, MD, MHSc, director, NAFLD Research Center, University of California San Diego, and coordinating investigator of the study. “The current standard of care for patients with NASH is suboptimal, and we anticipate the data from FASCINATE-2 will support advancing TVB-2640 into late-stage clinical trials.”

Click here to read the entire press release.